of moderate-or high-quality rating of the evidence, and a conditional recommendation in the presence of very-low or low-quality evidence (although recommendations can also be conditional in the setting of moderate-quality evidence, and in certain circumstances strong in the face of low-quality evidence) Limitations of the guideline include the limited comparative evidence to inform selection of therapies (i.e., primary comparative benefit/efficacy and harms evidence) and the inability to